Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.

Torres-Collado AX, Jazirehi AR.

Cancers (Basel). 2018 Jun 14;10(6). pii: E200. doi: 10.3390/cancers10060200.

2.

Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).

Torres-Collado AX, Knott J, Jazirehi AR.

Cancers (Basel). 2018 May 24;10(6). pii: E157. doi: 10.3390/cancers10060157. Review.

3.

Rescue of cell cycle progression in BRAFV600E inhibitor-resistant human melanoma by a chromatin modifier.

Toress-Collado AX, Nazarian R, Jazirehi AR.

Tumour Biol. 2017 Sep;39(9):1010428317721620. doi: 10.1177/1010428317721620.

PMID:
28936920
4.

Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

Dinh TN, Onea AS, Jazirehi AR.

Am J Clin Exp Immunol. 2017 May 15;6(3):27-42. eCollection 2017. Review.

5.

PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.

Jazirehi AR, Lim A, Dinh T.

Am J Cancer Res. 2016 Oct 1;6(10):2117-2128. eCollection 2016. Review.

7.

Epigenomics and targeted therapy in cancer.

Nazarian R, Jazirehi AR.

Epigenomics. 2014;6(6):571-5. doi: 10.2217/epi.14.72. No abstract available.

PMID:
25531250
8.

Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.

Jazirehi AR, Nazarian R, Torres-Collado AX, Economou JS.

Am J Clin Exp Immunol. 2014 Feb 27;3(1):43-56. eCollection 2014.

9.

Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.

Jazirehi AR, Kurdistani SK, Economou JS.

J Immunol. 2014 Apr 15;192(8):3981-9. doi: 10.4049/jimmunol.1302532. Epub 2014 Mar 17.

10.

Epigenetic biomarker of metastatic melanoma.

Torres-Collado AX, Jazirehi AR.

Epigenomics. 2013 Aug;5(4):366. No abstract available.

PMID:
24303558
11.

Epigenetic regulation of retinoic acid susceptibility in leukemia.

Torres-Collado AX, Jazirehi AR.

Epigenomics. 2013 Aug;5(4):365-66. No abstract available.

PMID:
24303557
12.

Prevalence of DNA methyltransferase in breast cancer by SNP analysis.

Jazirehi AR, Torres-Collado AX.

Epigenomics. 2013 Aug;5(4):365. No abstract available.

PMID:
24303556
13.

Regulation of the apoptotic activity of the ING member of histone acetyltransferase and deacetylase complexes.

Jazirehi AR, Torres-Collado AX.

Epigenomics. 2013 Aug;5(4):364. No abstract available.

PMID:
24303555
14.

Epigenetic fine-tuning of NF-κB-Sox9 circuitry in cancer stem cells.

Jazirehi AR, Torres-Collado AX.

Epigenomics. 2013 Aug;5(4):363-64. No abstract available.

PMID:
24303554
15.

Role of miR-18b/MDM2/p53 circuitry in melanoma progression.

Jazirehi AR, Torres-Collado AX, Nazarian R.

Epigenomics. 2013 Jun;5(3):254. No abstract available.

PMID:
24303553
16.

Circumvention of drug-resistance via decitabine-mediated DNMT1 depletion.

Torres-Collado AX, Jazirehi AR.

Epigenomics. 2013 Jun;5(3):253-54. No abstract available.

PMID:
24303552
17.

TFPI2 methylation can serve as an epigenetic biomarker of metastatic melanoma.

Nazarian R, Jazirehi AR.

Epigenomics. 2013 Jun;5(3):252-53. No abstract available.

PMID:
24303551
18.

Epigenetic regulation of melanoma tumor suppressor miRNA-124a.

Jazirehi AR, Torres-Collado AX, Nazarian R.

Epigenomics. 2013 Jun;5(3):251-52. No abstract available.

PMID:
24303550
20.

Is there a decrease in Keap1 RNA expression in colorectal cancer cells, and is this decrease in expression due to hypermethylation?

Jazirehi AR, Wenn PB, Arle D.

Epigenomics. 2012 Jun;4(3):253-4. No abstract available.

PMID:
22872918
21.

Role of epigenetic modifications of SOX 9 in gastric carcinoma.

Jazirehi AR, Arle D, Wenn PB.

Epigenomics. 2012 Jun;4(3):253. No abstract available.

PMID:
22872917
22.

Does the proliferation of human lymphoma cells depend on the mutation of EZH2 and consequential epigenetic modification of H3K27?

Jazirehi AR, Arle D, Wenn PB.

Epigenomics. 2012 Jun;4(3):252. No abstract available.

PMID:
22872916
23.

T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.

Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS.

J Transl Med. 2012 Jun 19;10:127. doi: 10.1186/1479-5876-10-127.

24.

UHRF1: a master regulator in prostate cancer.

Jazirehi AR, Arle D, Wenn PB.

Epigenomics. 2012 Jun;4(3):251-2. doi: 10.2217/epi.12.27. No abstract available.

25.

Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Jazirehi AR, Economou JS.

Mol Cancer Ther. 2012 Jun;11(6):1332-41. doi: 10.1158/1535-7163.MCT-11-0814. Epub 2012 Apr 24. Retraction in: Mol Cancer Ther. 2017 May;16(5):977.

26.

Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy.

Jazirehi AR, Wenn PB, Damavand M.

Am J Cancer Res. 2012;2(2):178-91. Epub 2012 Feb 15.

27.
28.
29.
30.

Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.

Jazirehi AR, Bonavida B.

Methods Mol Biol. 2011;731:407-19. doi: 10.1007/978-1-61779-080-5_33.

PMID:
21516425
31.

Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.

Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS.

Cancer Res. 2011 Feb 15;71(4):1406-17. doi: 10.1158/0008-5472.CAN-10-1296. Epub 2010 Dec 15. Retraction in: Cancer Res. 2017 Jul 1;77(13):3718.

32.

Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.

Jazirehi AR.

Anticancer Drugs. 2010 Oct;21(9):805-13. doi: 10.1097/CAD.0b013e32833dad91. Review.

PMID:
20679890
33.

Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.

Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.

Clin Cancer Res. 2009 Nov 1;15(21):6582-94. doi: 10.1158/1078-0432.CCR-09-1234. Epub 2009 Oct 27.

34.

The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.

Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B.

Leuk Lymphoma. 2008 Oct;49(10):1982-94. doi: 10.1080/10428190802357071.

PMID:
18949621
35.

Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.

Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B.

J Immunol. 2008 May 1;180(9):6199-210.

36.

Pioneer factor interactions and unmethylated CpG dinucleotides mark silent tissue-specific enhancers in embryonic stem cells.

Xu J, Pope SD, Jazirehi AR, Attema JL, Papathanasiou P, Watts JA, Zaret KS, Weissman IL, Smale ST.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12377-82. Epub 2007 Jul 18.

37.
38.

Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation.

Hongo F, Garban H, Huerta-Yepez S, Vega M, Jazirehi AR, Mizutani Y, Miki T, Bonavida B.

Biochem Biophys Res Commun. 2005 Oct 21;336(2):692-701.

PMID:
16143308
39.

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.

Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B.

Oncogene. 2005 Dec 8;24(55):8114-27.

PMID:
16103877
43.
44.

Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis.

Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B.

Adv Cancer Res. 2004;91:169-200. Review.

PMID:
15327891
47.

Quantitative structure-activity relationships of phenolic compounds causing apoptosis.

Hansch C, Bonavida B, Jazirehi AR, Cohen JJ, Milliron C, Kurup A.

Bioorg Med Chem. 2003 Feb 20;11(4):617-20.

PMID:
12538027
48.

Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine.

Emmanouilides C, Jazirehi AR, Bonavida B.

Cancer Biother Radiopharm. 2002 Dec;17(6):621-30.

PMID:
12537665

Supplemental Content

Loading ...
Support Center